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Abstract This prospective study investigated the effec-
tiveness of a three-tier modularized out- and inpatient mul-
tidisciplinary integrated headache care program. N = 204
patients with frequent headaches (63 migraine, 11 tension-
type headache, 59 migraine ? tension-type headache, 68
medication-overuse headache and 3 with other primary
headaches) were enrolled. Outcome measures at baseline,
6- and 12-month follow-ups included headache frequency,
Migraine Disability Assessment (MIDAS), Hospital Anxiety
and Depression Scale (HADS), standardized headache diary
and a medication survey. Mean reduction in headache fre-
quency was 5.5 ± 8.5 days/month, p \ 0.001 at 6 months’
follow-up and 6.9 ± 8.3 days/month, p \ 0.001 after
1 year. MIDAS decreased from 53.0 ± 60.8 to 37.0 ± 52.4
points, p \ 0.001 after 6 months and 34.4 ± 53.2 points,
p \ 0.001 at 1 year. 44.0 % patients demonstrated at base-
line an increased HAD-score for anxiety and 16.7 % of
patients revealed a HAD-score indicating a depression. At
the end of treatment statistically significant changes could
be observed for anxiety (p \ 0.001) and depression
(p \ 0.006). The intake frequency of attack-aborting
medication decreased from 10.3 ± 7.3 days/month at
admission to 4.7 ± 4.1 days/month, p \ 0.001 after
6 months and reached 3.8 ± 3.5 days/month, p \ 0.001
after 1 year. At baseline 37.9 % of patients had experience
with non-pharmacological treatments and 87.0 % at
12-month follow-up. In conclusion, an integrated headache
care program was successfully established. Positive health-
related outcomes could be obtained with a multidisciplinary
out- and inpatient headache treatment program.
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Chronic headache refers to a heterogeneous group of
headache disorders causing severe burden of disease on
society and involves high costs in healthcare systems.
Chronic headache reduces quality of life, decreases social
and job functioning and increases utilization of headache-
related services. Accordingly, headache disorders are
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amongst the top ten causes of disability [1, 2]. Increasing
headache frequency often leads to frequent intake of trip-
tans and analgesics resulting in medication overuse head-
ache (MOH), which is a complication of headache
treatment and is characterized by a headache occurring on
15 or more days per month for more than 3 months [3, 4].
However, medication overuse can cause chronic headache
in patients suffering from a primary headache disorder [5].
In clinical practice, chronic headache is mainly represented
by these three headache disorders, which have major sig-
nificance for public health because they are common and
responsible for almost all headache-related burden [6].
However, chronic headache is difficult to treat. Despite
advances in acute and prophylactic treatment of primary
headaches, many headache sufferers remain misdiagnosed
and undertreated [7–9]. In general, standard care therapy
for headache patients is provided by general practitioners
and neurologists in private practice. But most of primary
care physicians are not specialized in headache care.
Moreover, structured concepts of headache treatment using
effectively primary, secondary and tertiary health care
systems do not exist in many countries [6]. Additionally,
overprotected or unrestricted access to headache specialists
induces probably further complications, which will lead to
higher costs or blocking of restricted personal resources for
the therapy of difficult-to-treat headache patients. These
problems result in ineffective headache diagnosis and
treatment, which leads headache patients to repeated con-
sultations of different disciplines, expenditure on alterna-
tive therapies and unnecessary hospitalizations. Patients
with chronic headache utilize more health care resources
and claim twice as much medication compared with
patients with other diseases resulting in high indirect and
direct costs [2, 10].
Some multidisciplinary headache programs have already
been established for patients with frequent refractory
headaches [11–25], but documentation of organization, as
well as published outcome and follow-up data for periods
longer than 3 to 6 months, is still sparse. Although there is
sufficient evidence that mood and affective disorders affect
the outcome in chronic headache patients, most of the
available studies lack data on psychiatric comorbidities
[26, 27]. In order to overcome these problems in daily
practice, we developed a multidisciplinary headache
treatment program in a tertiary headache center in Berlin,
Germany, that entails a comprehensive assessment
including a headache diagnosis according to ICDH-II cri-
teria [28], screening for psychiatric comorbidity and mus-
culoskeletal disorders and provides treatment according to
clinical guidelines [29, 30]. Our integrated headache care
program follows the recommendations of a three-tier
interdisciplinary system [6]. The multidisciplinary head-
ache treatment program started in 2006 in cooperation with
selected health insurance companies and the University
Hospital in Essen, Germany, which initiated a similar
integrated headache care program in 2005 [24, 31]. Here,
we report prospectively collected baseline, 6- and
12-month follow-up data from frequent migraine, TTH and
MOH and/or difficult-to-treat chronic headache patients.
All questionnaires were administered on a pocket PC.
Follow-up focused on changes in headache frequency and
headache disability using MIDAS Questionnaire [32, 33].
Psychiatric comorbidity of anxiety and depression was
documented by HAD-Scale [34]. Additionally, the intake
frequency and an overuse of attack-aborting medications
(analgesics and triptans), use of prophylactic headache
medication and non-pharmacological treatments according
the recommendations of the German Headache and
Migraine Society [29, 30] were further follow-up parame-
ters. Primary and secondary responder rates and outcomes
in modules are reported separately.
Methods
Organization
The Headache Center Berlin (HCB) was inaugurated in
2006 as a tertiary headache clinic and provided an outpa-
tient and day clinic service for patients with chronic fre-
quent and/or difficult-to-treat headaches. Inpatient
treatment facilities (five beds) for patients with medication
overuse and severe psychiatric comorbidity were available
in cooperation with the Sankt Gertrauden Hospital Berlin,
Germany. The main uptake area was Berlin and the north-
eastern districts of Germany with a population of
7,600,000. The capacity was 750 new patients per year.
The staff in the Headache center consisted of one full-time
senior headache specialist supplemented by one full-time
junior doctor, two part-time behavioural psychologists and
two physical and sports therapists, one full-time nurse and
one secretary, with consultants from psychiatry, otorhino-
laryngology, ophthalmology, internal medicine and den-
tistry. Patients had to be referred by health insurances or
neurologists. The HCB cooperated with a network of
headache specialists (secondary care). All network partners
were connected with the HCB by a specifically dedicated
computer documentation system for online documentation
and collection of patient data [35]. At the HCB, European
Headache Federation guidelines for the organization of
headache clinics were implemented [11].
Study design
This was a prospective observational, non-randomized
study reporting the outcome in patients suffering from high
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frequency and/or difficult-to-treat headaches following the
integrated headache care program of the HCB. All patients
gave written informed consent prior to participation. The
project was approved by the local Ethics Committee. Adult
patients (C18 years) with headache diagnosis of migraine,
tension-type headache (TTH), combination headache and/
or MOH according to ICHD-II criteria [28] referred to the
HCB for the first time between 3/2009 and 9/2009 were
consecutively enrolled.
Procedures
Patients were referred by physicians or specialists when
headache treatment failed. In addition, health insurance
companies identified eligible patients on the basis of
inpatient data, sick leave or records of prescribed medi-
cation. Prior to the first visit, all participants kept a stan-
dardized headache diary (http://www.dmkg.de/dmkg/sites/
default/files/ks_kal.pdf) for at least 4 weeks. Initial ses-
sions consisted of an individual comprehensive assessment
by a neurologist, a psychologist and a physical therapist
taking one-hour face-to-face contact for each. If necessary,
additional diagnostic tests (imaging, blood test, etc.) and
consultations with further disciplines were performed. A
headache diagnosis was made according to ICHD-II cri-
teria [28]. The psychologist obtained information about the
patient’s level of stress, emotional well-being, job satis-
faction, life events and possible psychological headache
triggers. Mental disorders were diagnosed clinically by a
standardized interview using DIPS methodology [36] and
classified based on ICD-10 criteria [28]. A physical ther-
apist examined posture and muscle function and instructed
patients in active exercises and in the identification and
avoidance of possible muscular stress factors. Passive
treatment strategies, such as massage, were not performed.
Additionally, patients completed several questionnaires.
All questionnaires were administered on a pocket PC
using AC-STB software from Akkaya company, Cologne,
Germany; [35]. The Migraine Disability Assessment
(MIDAS) Questionnaire [32, 33] was developed to assess
headache-related disability. Headache-related quality of
life was assessed using the 12-item Short-Form Health
Survey (SF12 [37], German version: [38]. The SF12 con-
tains 2 subscales of functioning (‘‘physical’’/‘‘psychologi-
cal’’). The Hospital Anxiety and Depression Scale (HADS,
(German: [36]) was used to assess depression and anxiety.
The HADS is recommended for patients with somatic
problems [39]. Subsequent to the assessment, both team
and patient met in a pain conference and made a joint
decision about further treatment, which was realized in
co-operation between the HCB and the corresponding
network headache specialists. The managed care system
entailed a modularized treatment protocol. Patients were
assigned to one of three treatment modules taking into
consideration headache frequency, medication overuse and
psychiatric comorbidity.
Module 1: Moderate chronicity—Patients with a head-
ache frequency between 6 and less than 10 days/month and
less than 10 days with analgesics/triptans intake were
assigned to this module. Treatment included education and
patient self-management for preventing headache episodes.
If necessary, medication was optimized and patients were
treated near their place of residence by the complementary
specialists. A joint patient file, medical letters and follow-
up documentations were transmitted using the AC-STB
software [35].
Module 2: Severe chronicity—Patients with more than
10 headache days/month and more than 10 days with
analgesics/triptans intake were assigned to this module.
Patients received module 1 treatment and took part in a
multidisciplinary treatment program (MTP) at the HCB.
MTP consisted of a maximum of 12 additional outpatient
sessions on five consecutive days from 9.00 am to 4.00 pm
with a break of 1 h (30 h of therapy). The program entailed
group sessions of maximum 12 patients and included
individual appointments with the neurologist, psychologist
and the physical therapist if needed. The senior neurologist
provided headache education (90 min per day) focussing
on informing patients about etiology and pathophysiology
and the symptoms of primary headaches and MOH, med-
ical and non-pharmacological treatment options, and cor-
rect use, efficacy and possible adverse effects of acute and
prophylactic medication. The psychologist provided cog-
nitive-behavioural pain management (90 min per day).
Psychological group sessions focused on recommendations
of lifestyle for headache sufferers, and discussion of indi-
vidual headache concepts, individual styles of coping with
headache, avoidance of headache triggers and stress man-
agement. Furthermore, patients performed progressive
muscle relaxation therapy (PMR; 60 min per day). All
patients received a CD to enable them to practice PMR at
home daily. The physical training comprised endurance
sport, physical therapy and Nordic walking (60 min per
day). One important component of the behavioural therapy
concept was to motivate the patient at all levels during the
treatment program to immediately integrate the newly
gained knowledge and non-drug treatment techniques in
daily life.
Module 3: Severe chronicity with additional problems—
Patients with more than 15 headache days/month and more
than 15 days with analgesics/triptans intake and severe
psychiatric comorbidity or psycho-social problems, which
made withdrawal at home impossible, were assigned to this
module. They received module 1 and 2 treatment and apart
from participating in the MTP, they were hospitalized for a
maximum of 5 days and underwent drug withdrawal.
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Treatment entailed initiating adequate acute and prophy-
lactic drug management.
Baseline and follow-up data
The baseline data and the follow-up survey at 12 months
were performed by face-to-face interviews with the phy-
sicians and medical staff of the HCB, while 6-month data
were collected by the network headache specialists of the
integrated care system. These data were administered using
AC-STB software from Akkaya company, Ko¨ln, Germany
[35]. Demographic and personal data were obtained at
baseline as well as attack-aborting and prophylactic med-
ication and use of non-pharmacological treatments. The
course of these data and the headache frequency during
the one-year follow-up were reported by the patients on the
basis of prospective headache diaries. Burden of disease
was measured using the MIDAS Questionnaire. Further
key areas covered in the instruments included measurement
of depression and anxiety using the HAD-Scale. All these
data were documented by the patients on a hand-held PC
using AC-STB software. Information concerning psycho-
social status was obtained on a voluntary basis.
Data analyses
Depending on the type of outcome variables, differences of
data between measurement points (baseline—6 months—
12 months) were computed either with Student t test for
continuous variables or Mann–Whitney U test when vari-
ables were not normally distributed. We used Chi2 test for
comparisons of categorical variables. A p value of 0.05 was
considered significant. For better tracking statistical data
analyses we labeled also degrees of freedom (df) within the
text. All analyses were performed using IBM, Predictive
Analytics SoftWare (PASW), by SPSS, Version 19.0.0.
Results
Cohort and baseline data
A cohort of 337 chronic headache sufferers was consecu-
tively referred to the HCB between 3/2009 and 9/2009, of
whom 213 were qualified for participation in the multidis-
ciplinary integrated care program. 101 patients could not be
included because their insurances did not pay for them; they
received standard care. 23 patients had no chronic headache
disorders as defined in the treatment protocol for modules 1
to 3 or had headache diagnoses other than migraine, TTH or
MOH as defined as chronic headache disorder on more than
15 days/month caused by medication intake of attack
aborting drugs in patients suffering from a primary headache
disorder. Nine patients were excluded (n = 5 were lost for
personal reasons, n = 3 moved away and 2 became pregnant
and did not want to continue participating in the study
because they no longer had headaches). Table 1 summarizes
patient baseline characteristics (demographic and psycho-
social data) and headache diagnoses according to ICDH-II
criteria [28] of the 204 participants. Table 2 shows the
headache characteristics at baseline of the total cohort and
the patient subgroups. 31.9 % of patients were assigned to
module 1 (ambulatory), 55.9 % were treated in module 2
(day-clinic) and 12.2 % had in-patient treatment. At
admission, migraine patients revealed the lowest headache-
related disability (MIDAS: 39.5 ± 35.9), the lowest head-
ache frequency (8.9 ± 4.3 days/month) and the lowest
HAD-score for depression (4.34 ± 3.55), while MOH
patients had the highest burden of disease (MIDAS:
70.5 ± 73.0), the highest headache frequency (19.6 ±
7.5 days/month), the highest HAD-scores for depression
(6.38 ± 3.99) and anxiety (7.83 ± 4.72) and the highest rate
of missed school-/workdays per 3 months (35.2 ± 45.8).
The group of patients suffering from MOH (33.3 %) con-
sisted of patients with migraine and TTH (51.5 %), migraine
(42.6 %), TTH (2.9 %) and others (3.0 %) as the underlying
headache disorder. However, in this group 88.2 % reported a
withdrawal in medical history and of those, more than half
Table 1 Baseline patient characteristics and diagnoses
Total
Total 204
Age, mean (SD) 42.7 ? 13.4
Sex (male/female) 23/181
BMI, mean (SD) 24.1 ? 4.6
Education
Low education level (no or middle school) (%) 123 (65.1)
High education level (high school or higher) (%) 66 (34.9)
Total 189
Marital status
Single (%) 45 (29.2)
Partnership (%) 92 (59.8)
Others (%) 17 (11.0)
Total 154
Diagnoses
Migraine (%) 63 (30.9)
Without aura 50 (24.5)
With aura 13 (6.4)
Tension-type headache (%) 11 (5.4)
Episodic 6 (2.9)
Chronic 5 (2.5)
Migraine ? tension-type headache (%) 59 (28.9)
Medication-overuse headache (%) 68 (33.3)
Others (%) 3 (1.5)
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(53.3 %) had experienced more than one withdrawal. In
contrast, the group of TTH sufferers had the lowest rate of
missed school-/workdays per 3 months (16.3 ± 34.5), the
lowest number of days with attack-aborting medication
intake (5.1 ± 3.5 days/month) and the lowest HAD-score of
anxiety (5.67 ± 5.45). However, implementation of non-
pharmacological treatments was lowest in this subgroup at
admission (27.3 %), whereas patients suffering from
migraine and TTH had the most experience with these
techniques (47.5 %).
Outcomes
The course of headache days per month in the total cohort
and the headache subgroups at 6- and 12-month follow-ups
compared with baseline headache frequency is shown in
Fig. 1. Mean reduction in headache frequency was
5.5 ± 8.5 days per month, df = 174, p \ 0.001 during a
6-month period and 6.9 ± 8.3 days per month, df = 194,
p \ 0.001 after 1 year. A reduction in headache frequency of
C50 % was observed in 128/204 (62.7 %), a reduction of
C25 % and \50 % in 27/204 (13.2 %), while 40/204
(19.6 %) showed an unchanged frequency (\25 and C0 %)
and 9/204 (4.4 %) reported an increase of headache days
after one year. However, concerning the absolute reduction
of days with headache/month, MOH patients improved most
(mean -8.7 days per month) starting at the highest level of
headache frequency, followed by patients suffering from
migraine and TTH (mean -6.8 days per month), while
headache frequency decreased least in the group of migrai-
neurs (mean -4.1 days per month), which also had the
lowest level of headache frequency at baseline for absolute
Table 2 Headache characteristics at baseline of the total cohort and the subgroups of patients suffering from migraine, tension-type headache
(TTH), migraine and TTH and medication-overuse headache (MOH) and assignement to treatment modules
Total Migraine TTH Migraine ? TTH MOH
Number of patients 204 62 11 59 69
Duration of disease, Months, mean (SD) 240.4 ± 153.5 229.3 ± 151.7 141.8 ± 118.2 224.9 ± 137.2 279.8 ± 163.7
Headache frequency, days/month (SD) 14.5 ± 8.2 8.9 ± 4.3 15.3 ± 5.5 13.1 ± 7.5 19.6 ± 7.5
Intake frequency of attack-aborting medication, days/
month (SD)
10.3 ± 7.3 6.7 ± 3.2 5.1 ± 3.5 6.9 ± 3.9 17.5 ± 7.3
Missed school-/workdays/3 month 24.6 ± 32.3 18.7 ± 18.9 16.3 ± 34.5 19.8 ± 20.7 35.2 ± 45.8
Experience with non-pharmacological treatment (%) 37.9 40.3 27.3 47.5 36.2
MIDAS, mean (SD) 51.94 ± 56.95 39.53 ± 35.89 43.1 ± 79.1 45.55 ± 46.22 70.53 ± 73.00
HADS-depression, mean (SD) 5.29 ± 3.90 4.34 ± 3.55 5.00 ± 5.64 5.29 ± 3.61 6.38 ± 3.99
HADS-anxiety, mean (SD) 7.02 ± 4.16 6.00 ± 3.33 5.67 ± 5.45 7.65 ± 3.93 7.83 ± 4.72
SF 12—physical (SD) 40.75 ± 8.63 41.64 ± 7.74 42.80 ± 9.98 43.02 ± 8.56 38.02 ± 8.45
SF 12—mental (SD) 44.34 ± 10.61 47.09 ± 9.45 46.55 ± 13.94 44.38 ± 10.88 41.67 ± 10.31
Fig. 1 Course of headache
frequency (days/month)
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reduction of days with headache/month. Concerning the
relative reduction the decrease was similar among these
subgroups. An equally significant reduction of headache
frequency could also be observed in all modules after 6 and
12 months. The burden of disease was measured by MIDAS
and decreased in the total cohort from 53.0 ± 60.8 points to
37.0 ± 52.4 points, df = 107, p \ 0.001 after 6 months and
34.4 ± 53.2 points, df = 154, p \ 0.001 after 12 months.
Missed days at work/school per 3 months were 25.7 ± 35.0
at admission and 17.0 ± 31.9, df = 126, p \ 0.001 at
6 months and 16.8 ± 30.7, df = 166, p \ 0.002 at
12 months. Medication intake of attack-aborting drugs was
observed in 199/204 of patients (97.5 %) at baseline and
189/204 (92.6 %) at 12-month follow-up. The intake fre-
quency of attack-aborting medication was 10.3 ± 7.3 days/
month at admission, 4.7 ± 4.1 days/month, df = 186,
p \ 0.001 after a 6-month period and 3.8 ± 3.5 days/
month, df = 194, p \ 0.001 at 1-year follow-up. The high-
est reduction of medication intake frequency was found in
MOH patients (mean -12.3 days/month). A borderline
(8–10) or confirmatory (C11) HAD-score for depression was
found in 10.1/6.6 % (total 16.7 %) and for anxiety 25.0/
19.0 % (total 44.0 %) of patients. Mean scores for depres-
sion/anxiety at baseline were 5.29 ± 3.9/7.02 ± 4.2. Scores
for depression/anxiety were highest in the group of MOH
patients; mean: 6.
38 ± 3.99/7.83 ± 4.72, and lowest in migraineurs; mean:
4.34 ± 3.55/6.00 ± 3.33. There were no significant differ-
ences in depression/anxiety mean scores after 6 months in the
total cohort; 5.55 ± 4.44/5.63 ± 4.71, df = 63, p = 0.982//
7.11 ± 4.42/7.03 ± 3.95, df = 63, p = 0.743. In contrast,
mean scores for depression/anxiety showed significant dif-
ferences after 12 months; mean: 5.29 ± 3.90/5.07 ± 4.36,
df = 110, p = 0.006//7.02 ± 4.16/6.73 ± 4.20, df = 110,
p \ 0.001. Use of non-pharmacological evidence-based
treatments according the recommendations of the German
Headache and Migraine Society [31, 32] was observed in
77/204 (37.9 %) of headache sufferers at baseline and
168/193 (87.0 %) at 12-month follow-up.
Finally, the course of medication-overuse was analyzed
during the 1-year follow-up. At baseline, 69/204 patients
(33.8 %) had a medication-overuse. At the end of the study,
only 3/193 patients (1.6 %) had an overuse of attack-aborting
medications with an intake frequency of C15 days/month. All
of them were medication over-users at baseline; none of the
other patients participating in the study developed a medica-
tion-overuse within the 1-year follow-up period.
Discussion
An integrated care program was established to provide
multidisciplinary treatment of chronic headache sufferers
with frequent migraine, TTH or MOH and/or difficult-to-
treat headache. Integrated care at HCB focussed on a
comprehensive assessment including a headache diagnosis
according to ICDH-II criteria [28], standardized screening
for psychiatric comorbidity and provision of treatment
according to clinical guidelines [29, 30]. Patients were
assigned to three treatment modules following a simple
algorithm based on headache frequency, medication use
and psychiatric comorbidity. This procedure allowed a
valid patient assignment with regard to patients’ headache-
related disability and quality of life and tailored treatment
to patients’ needs. Recently, this criterion-based assign-
ment for modularized managed care headache treatment
has been validated by our study group [40]. A dedicated
computer documentation system [35] was introduced to
integrated headache care for the first time to enhance the
process quality and to realize cross-sectional communica-
tion between supply partners and the managed care clinic,
as well as online documentation, collection of data from
chronic headache patients and risk management.
This study demonstrates that a multidisciplinary in- and
outpatient integrated care program is effective in treating
chronic headache patients and results in a decrease of
burden of disease. Mean reduction in headache frequency
was 6.9 days per month at 1-year follow-up. In the present
study cohort, a significant difference of headache fre-
quency from baseline to 6- and 12-month follow-ups was
observed in all headache subgroups. Harpole et al. [14],
treating chronic headache patients in a multidisciplinary
management program, reported a reduction of 14.5 head-
ache days on average within 3 months. However, a
3-month follow-up measures mainly short-term effects.
Furthermore, in their study, 20 % of the patients had MOH
and suffered to 30 % from psychiatric comorbidities, while
burden of disease measured by MIDAS was 40.9 points on
average. In contrast, an alarming number of 33.8 %
patients participating in our study suffered from MOH with
a MIDAS-score of 52 points on average, indicating more
severely affected patients. A further study by Lemstra et al.
[13] reported a reduction of 33.6 % in pain frequency at
3-month follow-up in a small group of migraine patients
participating in a 6-week multidisciplinary treatment pro-
gram. In this study, headaches had existed on average for
101.7 months at baseline (in our study 240 months) and
Beck Inventory mean depression levels suggested marked
depressed mood levels. Maizels et al. [15] established a
group-based model of disease management for patients
with headache. During a 6-month period they recognized
that severe headache frequency was reduced in 86 % of
patients who initially had severe headaches more than
2 days per week. Recently, Gaul et al. [25] reported a
reduction of headache frequency of about 36.8 % after
1 year in a large cohort of headache patients treated in a
526 J Headache Pain (2012) 13:521–529
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non-modularized multidisciplinary integrated care pro-
gram. In a 6-month outcome study, Saper et al. [11]
assessed that 67 % of mainly physician-referred refractory
headache patients who participated in a comprehensive,
multidisciplinary, out- and inpatient treatment in a tertiary
headache center met the 50 % criterion for both parameters
of improvement of headache frequency and frequency of
severe headaches. Gaul et al. [24], treating 295 adult
patients with a headache-specific multidisciplinary pro-
gram, and Kabbouche et al. [41], treating children in a
comprehensive tertiary care, are the only authors reporting
1-year primary outcome data of multidisciplinary approa-
ches. Headache frequency decreased from 13.4 to 8.8 days/
month in adult chronic headache patients, while days with
headache/month were 13.4 at baseline and 4.9 after 1 year
in children. Jensen et al. [23] reported a reduction of
headache frequency from 20 days/month on admission to
11 days/month at the end of treatment after analyzing a
total of 1326 patients in a 2-year systematic follow-up
study in the Danish Headache Center. In their cohort,
25.5 % of patients had MOH, but unfortunately the authors
did not report data indicating burden of disease or psy-
chiatric comorbidity of patients. Furthermore, multidisci-
plinary integrated care as demonstrated in this study causes
a significant reduction of headache-related disability of
18.6 MIDAS points at 12-month follow-up. In the present
study, patients with TTH profited most in burden of disease
with a reduction of 27.7 MIDAS points, while migraineurs
experienced a MIDAS reduction of 11.8 points. This may
be due to the fact that in our cohort the TTH subgroup was
affected fewest consisting mainly of episodic TTH suffer-
ers (54.5 %), having the shortest history of disease, being
fewest anxious and consuming lowest amount of attack-
aborting medication/month. Additionally, we observed an
absolute reduction of 8.8 lost days at work/school per
3 months. These findings are in accordance with the
observations of Harpole et al. [14], who reported a reduc-
tion of 21.2 MIDAS points in their study, while Matchar
et al. [20] observed just a decrease of 14.9 points. Finally,
the present integrated care program was effective in
reducing intake frequency of attack-aborting medication
(days/month). Intake frequency decreased in the total
cohort by about 6.5 days/month and in MOH of about
12.3 days/month. However, medication consumption was
examined in just a few studies dealing with multidisci-
plinary headache treatment. In contrast to our findings,
Lemstra et al. [13] investigated a multidisciplinary man-
agement program for migraine treatment in comparison
with a control group and reported no significant changes in
medication use. Furthermore, Maizels et al. [15] studied
triptan costs for 6 months before and after intervention
using a group-based model of disease management in
patients with miscellaneous headaches (mainly transformed
migraine with medication overuse). They observed an
increase of 19 % in 6-month triptan costs during the
interventional phase. On the other hand, observations by
Gaul et al. [25] are in accordance with our findings. They
described a reduction of acute medication days with intake
of analgesics and triptans from 9 to 5 days/month in their
multidisciplinary treatment program, which had lifestyle
recommendations as an important element in their behav-
ioral treatment concept. Integrated headache care presented
in our study focusses likewise on cognitive-behavioral pain
management aspects and information about efficacy and
possible adverse effects of acute and prophylactic medi-
cation and its correct use in headache attack management.
Moreover, all patients learned PMR or get another non-
pharmacological treatment option in our integrated head-
ache care. The behavioral concept also expected the
patients to immediately integrate newly gained knowledge
about treating headache into their daily lives. Patients at all
treatment levels also received regular instruction to rein-
force what they had learned. In particular, cooperating
secondary care physicians were requested to provide their
headache patients with positive motivation to implement
the behavioral changes. Due to this, persistence of medi-
cation overuse for one year was documented in only 1.6 %
of patients in our study, while at baseline 33.8 % of par-
ticipants suffered from MOH. This is notable, because in
the present study the group of MOH patients was strongly
affected, had psychiatric comorbidity in 84 % of cases and
prior experience with withdrawal in 88 %; moreover, 53 %
of these had multiple withdrawal treatments. The 1-year
follow-up outcome after withdrawal of headache medica-
tion is assumed in the literature to be up to 40 % [42–47].
However, at the 1-year follow-up, no patients in our study
were identified with a newly developed MOH. Epidemio-
logical studies report an incidence for MOH of about
1–4 % [48–52]. In tertiary centers, by contrast, the inci-
dence of MOH reported in studies by Katzarava et al. [53]
may even be as high as 14 %. On the other hand only
37.9 % of our patients had experience with non-drug
methods of attack relief at baseline. At the end of treat-
ment, the number had risen to 87.0 %, of whom 75 %
regularly used PMR. This impressively illustrates that our
integrated headache care program results in a long-lasting
change in treatment style, away from passive measures and
acute medication overuse to an active coping strategy using
more non-pharmacological therapies.
A methodological strength of the presented study is its
prospective design, the large number of patients, classifi-
cation of patients according ICHD-II, a comprehensive
assessment including measurement of psychiatric comor-
bidity, implementation of a cross-sector computer docu-
mentation system and the long follow-up period of
12 months. The latter especially may help to distinguish
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between short- and long-term effects. The selected care-
research approach may better reflect reality than a con-
trolled study design. But this point also gives rise to a
major limitation of our study with a lack of control con-
dition. This non-randomized, open study was conducted at
a tertiary headache center taking care of severely affected
and chronic headache patients, which may lead to a typical
bias. But selection criteria for admission to the integrated
headache care could not be influenced by the authors.
Future studies should use controlled and randomized
design and should clarify the therapeutic role of the dif-
ferent components of treatment in integrated care.
In summary, the present study has provided support
for the usefulness of a multidisciplinary integrated care
program for severely affected and patients with difficult-
to-treat chronic headache, frequent migraine, TTH and
MOH. Integrated headache care led to a decrease in anxiety
and depression at 12-month follow-up. Further prospective
and controlled studies are needed to understand the role of
different components of integrated headache care.
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